

Contents

Chapter 1. Introduction

1.1. History and present state of mass spectrometry	3
1.2. Mass spectrometry for clinical medicine	7
1.3. Structure of this work	9
References	10

Chapter 2. Basic theory of mass spectrometry

2.1. Introduction	15
2.2. Mass spectrum	16
2.3. Ionizations	18
2.3.1. Electron ionization	18
2.3.2. Chemical ionization	20
2.3.3. Field desorption	23
2.3.4. Desorption chemical ionization	23
2.3.5. Atmospheric pressure chemical ionization	24
2.3.6. Plasma desorption	24
2.3.7. Thermospray ionization	25
2.3.8. Fast atom bombardment	25
2.3.9. Secondary ion mass spectrometry	27
2.3.10. Electrospray ionization	28
2.3.11. Matrix-assisted laser desorption ionization	30
2.4. Mass analyzer	31
2.4.1. Magnetic sector	31
2.4.1.1. Principle of magnetic sector analyzer	31
2.4.1.2. Double-focusing mass spectrometer	32
2.4.2. Quadrupole mass filter	33
2.4.3. Time-of-flight (TOF)	35
2.4.4. Ion trap (IT)	37
2.4.5. Fourier transform (FT)	38
2.5. Negative ion mass spectrometry (NIMS)	40
2.6. High resolution mass spectrometry (HRMS)	42

2.6.1.	Exact mass	42
2.6.2.	Resolution	42
2.6.3.	Calibration standards	44
2.7.	Gas chromatography/mass spectrometry (GC/MS)	50
2.7.1.	Interface	50
2.7.1.1.	Direct coupling	51
2.7.1.2.	Open-split coupling	51
2.7.1.3.	One-stage jet separator	54
2.7.2.	Selected ion monitoring (SIM)	54
2.7.3.	Mass chromatography (MC)	55
2.8.	Thin-layer chromatography/mass spectrometry (TLC/MS)	56
2.9.	Liquid chromatography/mass spectrometry (LC/MS)	56
2.9.1.	Thermospray ionization (TSI) LC/MS	57
2.9.2.	Particle beam (PB) LC/MS	58
2.9.3.	Atmospheric pressure chemical ionization (APCI) LC/MS	59
2.9.4.	Continuous-flow FAB (CF-FAB) LC/MS and frit-FAB-LC/MS	60
2.9.5.	Electrospray ionization (ESI) LC/MS	61
2.10.	Capillary zone electrophoresis/mass spectrometry (CZE/MS)	62
2.11.	Tandem mass spectrometry (MS/MS)	63
2.11.1.	MS/MS	63
2.11.2.	Collisional activation (CA) and collision-induced dissociation (CID)	66
2.11.3.	Linked scan	66
2.11.3.1.	Product ion scan	67
2.11.3.2.	Precursor ion scan	67
2.11.3.3.	Constant neutral loss scan	68
2.11.4.	MS/MS/MS (MS ³)	68
References		69

Chapter 3. Procedures for MS analysis of clinically relevant compounds

3.1.	Introduction	75
3.2.	Organic acids	76
3.2.1.	Extraction	76
3.2.1.1.	Urine	76
3.2.1.2.	Protein-containing fluids	79
3.2.2.	GC/MS	79
3.2.2.1.	Trimethylsilylation	79
3.2.2.2.	<i>tert</i> -Butyldimethylsilylation	81

	3.2.2.3. Methylation	82
	3.2.2.4. Oximation	82
	3.2.3. LC/MS	83
3.3.	Short-chain fatty acids	86
	3.3.1. Extraction	86
	3.3.2. GC/MS	87
3.4.	Volatile compounds	87
	3.4.1. Extraction	87
	3.4.2. GC/MS	91
3.5.	Polyols	91
	3.5.1. Extraction	91
	3.5.2. GC/MS	92
	3.5.3. LC/MS	94
3.6.	Amines	95
	3.6.1. Extraction	95
	3.6.2. GC/MS	97
	3.6.3. LC/MS	99
3.7.	Prostaglandins	99
	3.7.1. Extraction	99
	3.7.1.1. Organic solvent extraction	100
	3.7.1.2. Solid-phase extraction	100
	3.7.1.3. Immunoaffinity extraction	103
	3.7.2. Separation	104
	3.7.3. GC/MS	104
	3.7.4. LC/MS	106
3.8.	Steroids	107
	3.8.1. Extraction	107
	3.8.2. Separation	108
	3.8.3. Hydrolysis of conjugated steroids	109
	3.8.4. GC/MS	109
	3.8.5. LC/MS	110
3.9.	Bile acids	111
	3.9.1. Extraction	111
	3.9.2. Separation	111
	3.9.3. Hydrolysis of conjugated bile acids	112
	3.9.4. GC/MS	113
	3.9.5. LC/MS	114
	3.9.6. FAB-MS	114
3.10.	Amino acids	114
	3.10.1. Extraction	115

3.10.2. GC/MS	115
3.10.3. FAB-MS	117
3.11. Peptides and proteins	119
3.11.1. Cleavage of proteins to peptides	119
3.11.2. FAB-MS	121
3.11.3. ESI-MS	125
3.11.4. MALDI-MS	129
3.12. Nucleic acid constituents	131
3.12.1. Extraction	131
3.12.2. Hydrolysis of nucleic acids	133
3.12.3. GC/MS	135
3.12.4. LC/MS	136
3.12.5. FAB-MS	137
3.12.6. ESI-MS	139
3.12.7. MALDI-MS	139
References	140

Chapter 4. Mass spectrometry in uremia

4.1. Introduction	155
4.2. Search for uremic toxins	156
4.3. Organic acids	157
4.3.1. Free organic acids	158
4.3.2. Protein-bound organic acids	163
4.4. Phenols	170
4.5. Polyols	174
4.6. Steroids	181
References	184

Chapter 5. Mass spectrometry in diabetes mellitus

5.1. Introduction	191
5.2. Altered metabolism in diabetic ketoacidosis	192
5.2.1. Organic acids	192
5.2.2. Ketones	200
5.3. Metabolism of volatiles	200
5.4. Polyol metabolism	201
5.5. Glycation of proteins	206
References	217

Chapter 6. Mass spectrometry in Parkinson's disease

6.1. Introduction	223
-------------------	-----

6.2.	Metabolism of MPTP, a parkinsonism-producing compound	224
6.3.	Tetrahydroisoquinoline (TIQ) as a possible endogenous MPTP-like compound	230
6.3.1.	Discovery of TIQ in human parkinsonian brain	230
6.3.2.	Parkinsonism caused by TIQ in primates	233
6.3.3.	Metabolism of TIQ in the brain	235
6.3.4.	Presence of TIQ in foods	238
6.3.5.	Search for other TIQs in the brain	241
6.4.	L-DOPA and catecholamine metabolism	244
	References	247

Chapter 7. Mass spectrometry in hepatic diseases

7.1.	Introduction	253
7.2.	Bile acid metabolism	255
7.2.1.	Inborn errors of bile acid metabolism	256
7.2.1.1.	3β -Hydroxy- Δ^5 -C ₂₇ -steroid dehydrogenase deficiency	256
7.2.1.2.	3-Keto- Δ^4 -steroid 5 β -reductase deficiency	258
7.2.1.3.	Cerebrotendinous xanthomatosis (CTX)	260
7.2.1.4.	Peroxisomal disorders	261
7.2.2.	Bile acids in acquired hepatic diseases	263
7.2.2.1.	GC/MS	264
7.2.2.2.	FAB-MS and LSIMS	271
7.2.2.3.	LC/MS	275
7.3.	Bile alcohol metabolism	275
7.4.	Ammonia metabolism	280
7.5.	Metabolism of volatiles	280
7.6.	Organic acid metabolism	281
7.7.	Search for toxins causing hepatic encephalopathy	284
	References	286

Chapter 8. Mass spectrometry in disorders of organic acid metabolism

8.1.	Introduction	293
8.2.	Propionic acidemia	302
8.2.1.	Clinical features	302
8.2.2.	Metabolism	302
8.2.3.	Diagnosis and analysis	304
8.2.4.	Application of FAB-MS	309
8.3.	Methylmalonic aciduria	310

8.3.1.	Clinical features	310
8.3.2.	Metabolism	311
8.3.3.	Diagnosis and analysis	312
8.4.	Isovaleric acidemia	314
8.4.1.	Clinical features	314
8.4.2.	Metabolism	315
8.4.3.	Diagnosis and analysis	316
8.5.	Glutaric aciduria type 1	317
8.5.1.	Clinical features	317
8.5.2.	Metabolism	319
8.5.3.	Diagnosis	319
8.5.4.	Application of FAB-MS	321
8.6.	Glutaric aciduria type 2	322
8.6.1.	Clinical features	322
8.6.2.	Metabolism	322
8.6.3.	Diagnosis and analysis	322
8.7.	β -Ketothiolase deficiency (2-methylacetoacetic aciduria, 2-methyl-3-hydroxybutyric aciduria)	324
8.7.1.	Clinical features	324
8.7.2.	Metabolism	324
8.7.3.	Diagnosis	325
8.8.	3-Methylcrotonylglycinuria (3-methylcrotonyl-CoA carboxylase deficiency)	326
8.8.1.	Clinical features	326
8.8.2.	Metabolism	326
8.8.3.	Diagnosis	327
8.9.	3-Hydroxy-3-methylglutaric aciduria	327
8.9.1.	Clinical features	327
8.9.2.	Metabolism	329
8.9.3.	Diagnosis	329
8.10.	2-Ketoadipic aciduria	330
8.10.1.	Clinical features	330
8.10.2.	Metabolism	330
8.10.3.	Diagnosis	332
8.11.	Phenylketonuria	334
8.11.1.	Clinical features	334
8.11.2.	Metabolism	334
8.11.3.	Diagnosis and analysis	335
8.11.4.	Recent research	336
8.12.	Tyrosinemia type 1	336

8.12.1. Clinical features	337
8.12.2. Metabolism	338
8.12.3. Diagnosis and analysis	338
8.12.4. Prenatal diagnosis	339
8.13. Tyrosinemia type 2	341
8.13.1. Clinical features	341
8.13.2. Metabolism	341
8.13.3. Diagnosis	341
8.14. Alcaptonuria	341
8.14.1. Clinical features	341
8.14.2. Metabolism	342
8.14.3. Diagnosis	343
8.15. Pyroglutamic aciduria	343
8.15.1. Clinical features	343
8.15.2. Metabolism	343
8.15.3. Diagnosis	345
8.16. Maple syrup urine disease	345
8.16.1. Clinical features	345
8.16.2. Metabolism	346
8.16.3. Diagnosis and analysis	347
8.17. Dihydrolipoyl dehydrogenase deficiency	347
8.17.1. Clinical features	347
8.17.2. Metabolism	348
8.17.3. Diagnosis	349
8.18. Fumaric aciduria	349
8.18.1. Clinical features	349
8.18.2. Metabolism	350
8.18.3. Diagnosis	350
8.19. Glyceroluria	351
8.19.1. Clinical features	351
8.19.2. Metabolism	351
8.19.3. Diagnosis	351
8.20. 4-Hydroxybutyric aciduria	352
8.20.1. Clinical features	352
8.20.2. Metabolism	353
8.20.3. Diagnosis and analysis	354
8.21. 2-Hydroxyglutaric aciduria	354
8.21.1. Clinical features	354
8.21.2. Metabolism	354
8.21.3. Diagnosis	354

8.22.	2-Hydroxybutyric aciduria	355
8.22.1.	Clinical features	355
8.22.2.	Metabolism	355
8.22.3.	Diagnosis	355
8.23.	3-Methylglutaconic aciduria	355
8.23.1.	Clinical features	355
8.23.2.	Metabolism	356
8.23.3.	Diagnosis	356
8.24.	Primary hyperoxaluria	356
8.24.1.	Clinical features	356
8.24.2.	Metabolism	357
8.24.3.	Diagnosis and analysis	357
8.25.	D-Glyceric aciduria	357
8.25.1.	Clinical features	357
8.25.2.	Metabolism	358
8.25.3.	Diagnosis	358
8.26.	Dihydropyrimidine dehydrogenase deficiency	358
8.26.1.	Clinical features	358
8.26.2.	Metabolism	358
8.26.3.	Diagnosis	359
8.27.	Multiple carboxylase deficiency	359
8.27.1.	Clinical features	359
8.27.2.	Metabolism	360
8.27.3.	Diagnosis	361
8.28.	Mevalonic aciduria	361
8.28.1.	Clinical features	361
8.28.2.	Metabolism	361
8.28.3.	Diagnosis	362
8.29.	Ornithine transcarbamylase deficiency	363
8.29.1.	Clinical features	363
8.29.2.	Metabolism	363
8.29.3.	Diagnosis	364
8.29.4.	Recent research	364
8.30.	Dicarboxylic aciduria	365
8.30.1.	Diagnosis	365
8.30.2.	Inherited defects in mitochondrial β -oxidation	368
8.30.2.1.	Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency	368
8.30.2.2.	Long-chain acyl-CoA dehydrogenase (LCAD) deficiency	369

8.30.2.3. Short-chain acyl-CoA dehydrogenase (SCAD) deficiency	369
8.30.2.4. Long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency	369
8.30.2.5. Short-chain 3-hydroxyacyl-CoA dehydrogenase (SCHAD) deficiency	370
8.30.2.6. Glutaric aciduria type 2	370
8.30.2.7. Carnitine palmitoyltransferase (CPT) I deficiency	370
8.30.2.8. Carnitine palmitoyltransferase (CPT) II deficiency	370
8.30.2.9. Carnitine transport defect	370
8.30.2.10. Carnitine/acylcarnitine translocase deficiency	371
8.30.2.11. 2,4-Dienoyl-CoA reductase deficiency	371
8.30.3. Peroxisomal disorders	371
8.30.4. Other causes of dicarboxylic aciduria	372
8.30.4.1. Jamaican vomiting sickness	372
8.30.4.2. Reye's syndrome	373
8.30.4.3. Glycogen storage disease type 1 and type 3	373
8.30.4.4. Medium-chain triglyceride milk and valproic acid	373
References	374
<i>Subject index</i>	385